We are new company focused on the research and discovery of a portfolio of small-molecule therapeutics aimed to revolutionize the current standards of lung disease treatments.

Contact Us

Currently, there are no FDA approved therapies to stimulate regrowth of healthy lung tissue.

Next Generation Lung Care

Pneumonia is a leading cause of death in both infant and elderly populations. It is common to see patients rapidly progress to severe illness requiring hospitalization and intensive care, followed by prolonged suffering and recovery of the lung tissue. Therefore, to accelerate recovery pneumonia patients and improve odds of survival, we are developing a novel therapeutic for the regeneration of damaged lung tissue. By “mimicking” well-regulated, natural healing in the lungs, we propose an innovative approach to the clinical treatment of respiratory illnesses.

Our proprietary therapy aims to promote the proliferation of lung epithelial progenitor cells by re-activating mechanisms that are present during embryonic development. We have recently shown that intravenous delivery of our therapeutic can accelerate the proliferation of alveolar epithelial cells  into healthy lung tissue and improve survival and lung function of mice following bacterial pneumonia.


Wang Y, Li Y, Zhang P, Baker ST, Wolfson MR, Weiser JN, et al. Regenerative therapy based on miRNA- 302 mimics for enhancing host recovery from pneumonia caused by Streptococcus pneumoniae. Proc Natl Acad Sci U S A. 2019;116(17):8493-8.

Cutting Edge Research

Building on our existing strengths as a team of respiratory scientists and immunologists, Advac Therapeutics is backed by years of experience and top of the line methodologies. Advac Therapeutics has filed a number of U.S. Provisional Patent Applications through the Penn Center for Innovation to ensure the retention of inventor’s rights to any intellectual property arising from research conducted at our lab at the University of Pennsylvania.

[Read about the Shen Lab @ Upenn]